Bibliothek

feed icon rss

Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
Filter
  • Artikel: DFG Deutsche Nationallizenzen  (4)
  • Blood flow  (1)
  • Cremophor  (1)
  • Curvilinear-lamellar profiles  (1)
  • FMRFamide  (1)
  • 1
    Digitale Medien
    Digitale Medien
    Amsterdam : Elsevier
    Journal of Molecular and Cellular Cardiology 18 (1986), S. 91-97 
    ISSN: 0022-2828
    Schlagwort(e): Abnormal ECG ; Cardiac ceroid ; Curvilinear-lamellar profiles ; Quantitative fluorescence microscopy
    Quelle: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Thema: Medizin
    Materialart: Digitale Medien
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 2
    Digitale Medien
    Digitale Medien
    Amsterdam : Elsevier
    Respiration Physiology 61 (1985), S. 317-326 
    ISSN: 0034-5687
    Schlagwort(e): Blood flow ; Cardiac outpu ; Exercise ; Microsphere trapping ; Muscle ; Oxygen consumption
    Quelle: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002
    Thema: Medizin
    Materialart: Digitale Medien
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 3
    Digitale Medien
    Digitale Medien
    Springer
    Cancer chemotherapy and pharmacology 43 (1999), S. 13-18 
    ISSN: 1432-0843
    Schlagwort(e): Keywords Drug interaction ; Pharmacokinetics ; Cremophor ; Paclitaxel
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Medizin
    Notizen: Abstract Purpose: Cremophor can alter the pharmacokinetics of cytotoxic drugs, including doxorubicin and etoposide. In view of its presence in the formulation of paclitaxel, the aim of this study was to investigate the influence of Cremophor on the hepatobiliary elimination of paclitaxel. Methods: In a recirculating isolated perfused rat-liver system the elimination of 1.7 mg paclitaxel given as a bolus into the perfusate reservoir was monitored in perfusate and bile in controls and after the administration of either 80 or 800 μl Cremophor. The higher dose of Cremophor yields clinically relevant perfusate concentrations. Paclitaxel was measured in perfusate, bile, and liver tissue by high-performance liquid chromatography. Results: Cremophor caused a dose-dependent inhibition of the elimination of paclitaxel, with a statistically significant mean value ± SD, n = 3; (P 〈 0.05 versus controls Bonferroni t-test) 9-fold increase in AUC (2227±106 versus 245 ± 40 g ml−1min), 9-fold decrease in total clearance (0.8±0.1 versus 7.0±1.1 ml/min), and 5-fold increase in elimination half-life (92±14 versus 18±4 min) being observed after a dose of 800 μl Cremophor. With the addition of Cremophor the amount of paclitaxel remaining after 3 h increased in perfusate from none to 20, increased in liver tissue from 4 to 18, and remained constant in bile at 11–13%. In the control group, 86 of the paclitaxel dose was recovered in bile as five putative metabolites, which were measured in paclitaxel equivalents, with the major metabolite. M3 co-eluting with 3′-p-hydroxypaclitaxel. This decreased to 45 of the dose on the addition of Cremophor, and the ratio of M3 to paclitaxel in bile decreased. Conclusions: Cremophor inhibits the hepatic elimination of paclitaxel in the isolated perfused rat liver, primarily by preventing the drug from reaching sites of metabolism and excretion. The presence of Cremophor in the paclitaxel formulation may therefore contribute to the nonlinear pharmacokinetics and pharmacodynamics of paclitaxel.
    Materialart: Digitale Medien
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 4
    ISSN: 1432-136X
    Schlagwort(e): Key words Atrium ; Buccinum undatum ; FLRFamide ; FMRFamide ; Perfused ventricle ; AbbreviationsFLRFamide phenylalanine-leucine-arginine-phenylalanine-NH2 ; FMRFamide phenylalanine-methionine-arginine-phenylalanine-NH2 ; GTP guanosine triphosphate ; 5-HT 5-hydroxytryptamine ; IP3 inositol 1,4,5-trisphosphate
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Biologie , Medizin
    Notizen: Abstract In this study the relative potencies of four established molluscan cardioexcitatory agents were examined on Buccinum heart. The potencies were, in decending order: phenylalanine-leucine-arginine-phenylalanine-NH2 (FLRFamide) 〉 phenylalanine-methionine-arginine-phenylalanine-NH2 (FMRFamide; 80% of maximum) 〉 5-hydroxytryptamine (5HT; 60% of maximum) 〉 guanosine triphosphate (GTP; 15% of maximum). FMRFamide and FLRFamide had similar dose-response curve patterns with thresholds at 10−9 mol l−1 but FLRFamide was more potent than FMRFamide. The superfused atrium was much less sensitive to all agonists than the internally perfused ventricle. FLRFamide and FMRFamide induced small depolarizations (1–2 mV) which triggered a burst of action potentials of about 5 mV which on reaching 4 mV triggered a burst of fast twitch contractions. Lithium, at high concentrations inhibited FMRFamide and 5-HT responses of internally perfused ventricles. Neomycin also inhibited peptide responses, but was without effect on 5-HT responses. Heparin, however, for technical reasons was without effect on ventricular responses to all three agonists. FMRFamide and FLRFamide appear to share a common receptor, the potency difference being due to the substitution of leucine for methionine in FLRFamide. The RF N-terminal sequence appears crucial for receptor activation. The Phospholipase C inhibitor neomycin equally inhibits responses to the two peptides while 5-HT responses are unaffected. This implicates a peptide/receptor interaction which activated inositol 1,4,5-trisphosphate (IP3) as a second messenger.
    Materialart: Digitale Medien
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie hier...